Nohair Sultan Fahad Al
Department of Family Medicine, College of Medicine, Qassim University, Buraydah, Saudi Arabia.
Int J Health Sci (Qassim). 2021 Jul-Aug;15(4):4-9.
The current tools for the management of diabetes mellitus (DM) do not prevent its development or complications, so investigations into promising new treatments, for example, honey-royal jelly (H-RJ) mixtures, are needed. This study was conducted to evaluate the effect of royal jelly on DM by measuring the biochemical parameters (fasting blood glucose and glycated hemoglobin [HbA1c]) accompanying streptozotocin (i.p. 75 mg/kg once)-induced type 1 DM (T1DM) in rats. Other objectives were to evaluate the effects of H-RJ on lipid parameters.
Ten healthy control male Sprague-Dawley rats (120-150 g) were compared to untreated T1DM ( = 10), metformin-treated T1DM ( = 10), and H-RJ-treated T1DM rats ( = 10) on plasma and whole-blood glycemic control indices (fasting blood glucose, HbA1c %, insulin, and insulin resistance) and plasma lipid profile (triglycerides [TGs] and total, low-density lipoprotein -, high-density lipoprotein -, and very low-density lipoprotein [VLDL]-cholesterol). Diabetes was induced by a single intraperitoneal injection of streptozotocin (SZT) at 75 mg/kg body weight (BW). The T1DM-H-RJ rat group received daily RJ (100 mg/kg BW). Parametric data are presented as mean ± SD and were analyzed for comparison using one-way ANOVA in SPSS software.
H-RJ normalized glycemic control indices, but its effect on lipid parameters was variable. H-RJ and metformin had comparable effects. The H-RJ treatment caused a significant reduction in plasma VLDL-C content in comparison to the control treatment and metformin. The limitation of this study is that it was restricted to T1DM and did not involve type 2 DM. In addition, the study was limited to male Sprague-Dawley rats, with no females.
The H-RJ mixture is a promising antidiabetic alternative medicine. It effectively reduces VLDL-C and TG in diabetic rats.
目前用于管理糖尿病（DM）的工具无法预防其发展或并发症，因此需要对有前景的新疗法进行研究，例如蜂蜜-蜂王浆（H-RJ）混合物。本研究旨在通过测量链脲佐菌素（腹腔注射，75mg/kg，一次性）诱导的大鼠1型糖尿病（T1DM）伴随的生化参数（空腹血糖和糖化血红蛋白[HbA1c]）来评估蜂王浆对糖尿病的影响。其他目的是评估H-RJ对脂质参数的影响。
将10只健康对照雄性Sprague-Dawley大鼠（120-150g）与未治疗的T1DM大鼠（n = 10）、二甲双胍治疗的T1DM大鼠（n = 10）和H-RJ治疗的T1DM大鼠（n = 10）在血浆和全血糖控指标（空腹血糖、HbA1c%、胰岛素和胰岛素抵抗）以及血浆脂质谱（甘油三酯[TGs]和总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和极低密度脂蛋白[VLDL]胆固醇）方面进行比较。通过腹腔注射75mg/kg体重（BW）的链脲佐菌素（SZT）诱导糖尿病。T1DM-H-RJ大鼠组每天接受RJ（100mg/kg BW）。参数数据以平均值±标准差表示，并在SPSS软件中使用单因素方差分析进行比较分析。
H-RJ使血糖控制指标正常化，但其对脂质参数的影响是可变的。H-RJ和二甲双胍具有相当的效果。与对照治疗和二甲双胍相比，H-RJ治疗导致血浆VLDL-C含量显著降低。本研究的局限性在于它仅限于T1DM，未涉及2型糖尿病。此外，该研究仅限于雄性Sprague-Dawley大鼠，没有雌性大鼠。
H-RJ混合物是一种有前景的抗糖尿病替代药物。它能有效降低糖尿病大鼠的VLDL-C和TG。
